Decoy Therapeutics Inc. (DCOY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on September 14, 2026, regarding a Special Meeting of Stockholders convened by Decoy Therapeutics Inc. The filing details the voting results for corporate governance and capital structure proposals.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate actions and voting outcomes rather than financial performance.
Material Changes and Voting Results
As of the record date (July 20, 2026), there were 590,185 shares of common stock outstanding. A quorum was established with 271,643 shares (46.03%) present. Stockholders approved the following:
- Proposal 1 (Warrant Issuance): Approved the issuance of common stock upon the exercise of Series A, B, and C "Milestone Warrants."
- Votes For: 81,646
- Votes Against: 2,906
- Abstentions: 196
- Proposal 2 (Authorized Share Reduction): Approved an amendment to the Certificate of Incorporation to reduce authorized common shares by 10,000,000, resulting in a total of 90,000,000 authorized shares.
- Votes For: 234,494
- Votes Against: 6,303
- Abstentions: 181
- Proposal 3 (Adjournment): Rendered moot as Proposals 1 and 2 were approved.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risk factors. The primary operational implication is the potential dilution from the exercise of Milestone Warrants and the reduction of the company's authorized share pool.
Key Facts for Investor Verification
- Verify the total number of shares issued upon the exercise of the Series A, B, and C Milestone Warrants to assess actual dilution impact.
- Confirm the updated authorized share count of 90,000,000 in the company's amended Certificate of Incorporation.
- Review the terms of the Milestone Warrants to understand the conditions triggering the share issuance approved in Proposal 1.
- Note the low absolute number of outstanding shares (590,185) at the time of the vote, which may indicate a reverse stock split or significant capital restructuring occurred prior to this date.